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Endogenous Gonadal Hormone Exposure and Bone Sarcoma Risk1

Dawn M. Cooley, Benjamin C. Beranek,
Deborah L. Schlittler, Nita W. Glickman,
Lawrence T. Glickman, and David J. Waters2
Departments of Veterinary Clinical Sciences [D. M. C., B. C. B., D. L. S.,
D. J. W.] and Veterinary Pathobiology [N. W. G., L. T. G.], Purdue University,
West Lafayette, Indiana 47907, and the Gerald P. Murphy Cancer Foundation,
Seattle, Washington 98125 [D. M. C., D. J. W.]

Abstract
Although experimental and clinical evidence suggest that
endogenous sex hormones influence bone sarcoma
genesis, the hypothesis has not been adequately tested in
an appropriate animal model. We conducted a historical
cohort study of Rottweiler dogs because they frequently
undergo elective gonadectomy and spontaneously develop
appendicular bone sarcomas, which mimic the biological
behavior of the osteosarcomas that affect children and
adolescents. Data were collected by questionnaire from
owners of 683 Rottweiler dogs living in North America.
To determine whether there was an association between
endogenous sex hormones and risk of bone sarcoma,
relative risk (RR) of incidence rates and hazard ratios for
bone sarcoma were calculated for dogs subdivided on the
basis of lifetime gonadal hormone exposure. Bone
sarcoma was diagnosed in 12.6% of dogs in this cohort
during 71,004 dog-months follow-up. Risk for bone
sarcoma was significantly influenced by age at
gonadectomy. Male and female dogs that underwent
gonadectomy before 1 year of age had an approximate
one in four lifetime risk for bone sarcoma and were
significantly more likely to develop bone sarcoma than
dogs that were sexually intact [RR ⴞ95% CI ⴝ 3.8 (1.5–
9.2) for males; RR ⴞ95% CI ⴝ 3.1 (1.1– 8.3) for females].
2 test for trend showed a highly significant inverse doseresponse relationship between duration of lifetime
gonadal exposure and incidence rate of bone sarcoma
(P ⴝ 0.008 for males, P ⴝ 0.006 for females). This
association was independent of adult height or body
weight. We conclude that the subset of Rottweiler dogs
that undergo early gonadectomy represent a unique,
highly accessible target population to further study the
gene:environment interactions that determine bone
sarcoma risk and to test whether interventions can inhibit
the spontaneous development of bone sarcoma.
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Introduction
Osteosarcoma is the most frequently diagnosed bone tumor of
adolescents and young adults (1–3). To date, little is known
concerning etiology and risk factors for osteosarcoma. Limited
geographic variation in the incidence of osteosarcoma suggests
the importance of host factors such as gender or skeletal growth
(4). Age-specific incidence data indicate an association between the pubertal growth spurt and development of bone
sarcoma in adolescents (5– 8). The hypothesis that rapid skeletal growth or large body size confers increased risk of bone
sarcoma development has been proposed (6, 9, 10) but has not
been rigorously tested in an appropriate animal model. Annual
age-adjusted incidence rates for bone sarcoma are 1.0/100,000
males and 0.6/100,000 females (11). In one study, males were
four times more likely than females to die within 2 years of
bone sarcoma diagnosis (12). These data suggest that endogenous sex hormones may influence the development and biological behavior of these tumors.
Spontaneous osteosarcoma in pet dogs closely mimics its
human counterpart in terms of skeletal location, metaphyseal
involvement, aggressive biological behavior, high propensity
for pulmonary metastases, and response to cytotoxic chemotherapy (13–15). An estimated 10,000 cases of bone sarcoma in
pet dogs are diagnosed annually in the United States (13). An
association between body size and bone sarcoma risk in dogs is
well documented. Across different dog breeds, body size is the
strongest predictor of risk for osteosarcoma (16, 17). However,
no studies have used measures of body size such as adult height
or weight obtained from individual dogs of the same breed to
determine whether these factors significantly influence risk of
bone sarcoma.
Humans do not frequently undergo gonadectomy. In contrast, pet dogs frequently undergo elective gonadectomy, providing a unique population to study the influence of endogenous sex hormones on spontaneous bone sarcoma development.
Data collected from veterinary teaching hospitals suggested
that both male and female neutered dogs were at increased risk
for bone sarcoma (17). However, in that study, age at neutering
was not available, and thus, duration of exposure to gonadal
hormones for each dog could not be determined. To characterize the dose-response relationship between endogenous sex
hormones and bone sarcoma risk, a study providing information
on lifetime gonadal hormone exposure would be required.
To test the hypothesis that endogenous sex hormones
significantly influence bone sarcomagenesis, we conducted a
historical cohort study of Rottweiler dogs, a breed known to be
at high risk for bone sarcoma. In addition, we determined
whether adult height or body weight were significant risk
factors for bone sarcoma between individuals of the same
breed. Our results indicate that dogs undergoing early gonadectomy have a significantly higher risk of appendicular bone
sarcoma, suggesting that sex hormones may be important modifiers of bone sarcoma development.
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Materials and Methods
Study Population. We conducted an historical cohort study of
Rottweiler dogs in the pet population that were followed over
a significant proportion of their lifetime. Rottweiler dogs were
targeted for this study because they represent a breed at high
risk for appendicular bone sarcoma (17), a tumor bearing striking similarity to the osteosarcoma that affects children and
adolescents. In November 1999, a questionnaire was mailed to
1,500 owners of Rottweiler dogs identified through 8 national
Rottweiler breed specialty clubs.3 In addition, the questionnaire
was published in the national breed magazine, The Rottweiler
Quarterly (18). Purebred Rottweiler dogs of any age that were
alive on January 1, 1995, were eligible for study. Owners were
asked to complete one questionnaire per eligible dog, and a
maximum of five dogs could be entered per household. Data
from 730 questionnaires returned by March 1, 2000, were used
in this study.
Data Collection. With the assistance of a veterinarian, pet
owners completed a 12-page questionnaire consisting of 62
questions encompassing six categories: general owner information; general dog information; development of bone sarcoma;
familial history of cancer; exposure and trauma history; and
health conditions confirmed by a veterinarian. General owner
information included questions regarding number of Rottweilers owned, purpose of dog ownership (e.g., pet or working
dog), and place of residence. General dog information included
questions pertaining to date of birth, gender, date of neuter,
country of birth of this dog and two prior generations, housing
conditions, body condition (immature and adult), adult body
weight, adult height, growth rate, bone structure, diet, dietary
supplements, vital status, and date and cause of death, if applicable. Questions pertaining to bone sarcoma included age at
diagnosis, location of primary tumor, treatment, and survival.
Familial cancer history consisted of questions pertaining to the
owner’s knowledge of the development of a bone tumor or
other malignancy in siblings or first and second generation
relatives. Vaccination history, chemical exposures, and trauma
history were also obtained. The questionnaire also included a
checklist of 40 health conditions (13 cancer-related and 27
noncancer-related) confirmed by a veterinarian. Pet owners
were given the option to return the completed questionnaire
anonymously or to include their name, address, and their veterinarian’s contact information. Over 98% of returned questionnaires contained the identity of the owner and dog, including contact information, so that the accuracy of data could be
verified.
Ascertainment of Bone Sarcoma. A diagnosis of bone tumor
was reported for 133 dogs. Telephone follow-up with veterinarians and owners was conducted by two interviewers
(D. M. C., D. L. S.) to obtain more detailed diagnostic information for any dog with a reported bone sarcoma. Medical
records and available radiographs were reviewed by the authors
(D. J. W., D. M. C.) for each dog with a reported bone tumor.
Cases were included only if a diagnosis of appendicular bone
sarcoma was supported by radiographic or histological evidence of bone sarcoma. We limited our study to the bone
sarcomas of the appendicular skeleton because these tumors
most closely resemble osteosarcoma of children and adolescents (13). Forty-seven dogs with a reported bone tumor were

3
Medallion Rottweiler Club, Colonial Rottweiler Club, Delta Rottweiler Owners
Club, Emerald Valley Rottweiler Club, Great Lakes Rottweiler Club, Gulfstream
Rottweiler Club, Northstar Rottweiler Club, and Mile High Rottweiler Club.

excluded from the analyses because medical records were incomplete, radiographs were not consistent with long bone sarcoma, or histopathology was inconsistent with osteosarcoma.
The 47 dogs that were excluded did not differ significantly in
terms of key characteristics from the subcohort of 86 dogs with
appendicular bone sarcoma included in this analysis that satisfied the inclusion criteria. The subcohort without bone cancer
included all 597 dogs in this cohort that were free of bone
cancer.
Assessment of Gonadal Hormone Exposure and Other Risk
Factors. Dogs were categorized on the basis of neuter status
into four groups: castrated male; sexually intact male; spayed
female; and sexually intact female. Lifetime gonadal hormone
exposure of each dog was expressed in terms of total months of
gonadal hormone exposure (i.e., number of months sexually
intact). We analyzed risk for bone sarcoma using months of
gonadal hormone exposure as a continuous variable. In addition, we stratified dogs of each gender into four subgroups on
the basis of their duration of gonadal exposure. This stratification enabled us to evaluate the dose-response relationship between duration of gonadal exposure and bone sarcoma risk
within the study cohort. These subgroups included two biologically distinct groups representing the extremes of gonadal
hormone exposure (i.e., dogs neutered before skeletal maturation at ⬍1 year of age and dogs that remained sexually intact
for their entire lifetime). The remaining dogs that underwent
gonadectomy after 1 year of age were dichotomized into two
equal groups. For females, the gonadal hormone exposure subgroups were: spayed before 1 year of age; spayed between 1
and 5 years of age; spayed after 5 years of age; and sexually
intact. For males, the gonadal exposure subgroups were: castrated before 1 year of age; castrated between 1 and 3.5 years
of age; castrated after 3.5 years of age; and sexually intact.
Because body size is a potentially important risk factor for
appendicular bone sarcoma development, we evaluated adult
height and body weight for their possible association with bone
sarcoma in Rottweiler dogs. Adult height (cm) and body weight
(kg) were obtained from the questionnaire. To collect information on reproductive history, follow-up telephone interviews
were conducted with owners of 332 female Rottweiler dogs that
were sexually intact or spayed after 1 year of age. Successful
interviews were obtained from 275 (83%) of attempted contacts. Data obtained included number of litters, date of whelping, number of puppies per litter, and whether the dog had ever
received exogenous hormone treatment.
Statistical Analysis. Incidence of appendicular bone sarcoma
was calculated for the entire population, for each gender-neuter
category (castrated male, sexually intact male, spayed female,
and sexually intact female), and for each gonadal hormone
exposure subgroup. For each group, incidence rate of bone
sarcoma was calculated by determining the number of bone
sarcomas/10,000 dog-months at risk. To measure the strength
of association between gonadal hormone exposure and bone
sarcoma risk, RRs4 and 95% CIs for bone sarcoma incidence
rates were calculated. Sexually intact dogs were used as the
reference group (RR ⫽ 1.0) for both males and females. 2 test
for trend was used to analyze dose-response relationships
across different lifetime duration of gonadal hormone exposure.
Hazard ratios and 95% CIs were determined using Cox proportional hazard models to analyze lifetime duration of gonadal
hormone exposure as a continuous variable. Risk factors asso-

4

The abbreviations used are: RR, relative risk; CI, confidence interval.

Downloaded from cebp.aacrjournals.org on October 29, 2019. © 2002 American Association for Cancer Research.

1435

1436

Gonadal Hormones and Bone Sarcoma Risk

Table 1

Description of population of Rottweilers included in a historical
cohort study of bone sarcoma risk

No. of dogs
No. of households
Residence
United States (45 states)
Canada
Status at time of questionnaire
Alive
Deceased
Follow-up duration (mean; range)
Dogs with bone sarcoma
Dogs without bone sarcoma
Age at Death (mean ⫾ SD)
Intact male
Castrated male
Intact female
Spayed female
Dogs with bone sarcoma
Dogs without bone sarcoma
Appendicular bone sarcoma
Age at diagnosis (median; range)
Intact male
Castrated male
Intact female
Spayed female
Skeletal location
Proximal humerus
Distal radius
Distal femur
Distal tibia
Other
Cause of death (% of 305 deaths)
Cancer
Gastrointestinal disease
Neurological disease
Cardiovascular disease
Old age
Osteoarthritis
Renal disease
Endocrine disease
Other
Unknown

683
402
648 (94.9%)
35 (5.1%)
55%
45%
8.8 (1.3–13.2) yr
8.6 (1.7–15.6) yr
9.3 ⫾ 2.5 yr
9.2 ⫾ 2.5 yr
7.5 ⫾ 2.4 yr
9.8 ⫾ 2.4 yr
8.8 ⫾ 2.0 yr
9.5 ⫾ 2.6 yr
8.0
8.0
8.0
7.5
9.0

(1.3–13.0)
(5.0–12.0)
(5.0–13.0)
(4.0–9.0)
(1.3–11.0)

32
16
10
9
19

yr
yr
yr
yr
yr

(37.2%)
(18.6%)
(11.6%)
(10.5%)
(22.1%)

64.3%
7.2%
4.3%
3.9%
3.6%
3.3%
2.6%
2.6%
3.0%
5.2%

ciated with bone sarcoma in univariate analysis at P ⬍ 0.20
were tested in multivariate Cox proportional hazards models.
All data analyses were performed using standard computerized
statistical software (SPSS Version 10.0 and Epi Info ver 6.04),
and differences were considered to be statistically significant at
P ⬍ 0.05.
Results
Baseline characteristics of the 683 dogs in this cohort are shown
in Table 1. Eligible questionnaires were completed by owners
of purebred Rottweilers from 402 households in 45 states across
the United States and Canada. Approximately 45% of dogs
were dead at the time the questionnaire was completed with a
mean ⫾ SD age at death of 9.3 ⫾ 2.5 years. Mean ⫾ SD age
of dogs that were alive at the time of questionnaire was 8.1 ⫾
2.2 years. Cancer-related mortality was reported in 64.3% of
Rottweiler dogs in this cohort. The most common noncancer
causes of death were gastrointestinal diseases (7.2%), neurological diseases (4.3%), and cardiac diseases (3.9%).
Overall, the incidence of appendicular bone sarcoma in this
cohort was 12.6%. Eighty-six cases were diagnosed during 71,004
dog-months follow-up. Overall, mean ⫾ SD age at appendicular

bone sarcoma diagnosis was 8.3 ⫾ 1.9 years, which did not differ
significantly between different gonadal hormone exposure categories. Tumors most often affected the forelimb. Proximal humerus
and distal radius, the most frequent sites of appendicular bone
sarcoma reported in large and giant breed dogs, were the most
commonly affected skeletal sites in this population.
Females were more often diagnosed with bone sarcoma
than males, however, the difference was not statistically significant [hazard ratio (95% CI) ⫽ 1.01 (0.66 –1.55); P ⫽ 0.97]
(Table 2). Age at gonadectomy significantly influenced risk for
bone sarcoma. Both males and females that developed bone
sarcoma were sexually intact for significantly fewer months
than dogs that did not develop bone sarcoma (Table 2) [hazard
ratios (95% CI) ⫽ 0.98 (0.98 – 0.99) for males and 0.98 (0.97–
0.99) for females; P ⬍ 0.0001 for both]. In multivariate analysis, months intact remained significantly inversely associated
with bone sarcoma risk after controlling for gender, adult
height, and adult body weight (P ⬍ 0.0001; Table 3). For each
additional month of being sexually intact, there was a 1.4%
reduction in bone sarcoma risk.
To further evaluate the potential dose-response relationship
between risk of bone sarcoma and gonadal hormone exposure,
dogs were categorized into four subgroups for each gender based
upon lifetime duration of exposure to gonadal hormones. Table 4
shows the incidence rate of bone sarcoma (per 10,000 dogmonths) in each of the gonadal hormone exposure subgroups.
There was a significant negative association between gonadal
hormone exposure and risk of bone sarcoma (P for trend ⫽ 0.008
for males; 0.006 for females). In males, bone sarcoma incidence
rate for dogs castrated before 1 year of age (lowest gonadal
exposure) was 28.4 bone tumors/10,000 dog-months at risk, which
was almost four times greater than the rate of bone sarcoma in
sexually intact males [RR ⫾ 95% CI ⫽ 3.8 (1.5–9.2); P ⫽ 0.002].
In females, bone sarcoma incidence rate in dogs spayed before 1
year of age (lowest gonadal exposure) was 25.1 bone tumors/
10,000 dog-months at risk, which was more than three times
greater than the rate in sexually intact females [RR ⫾ 95% CI ⫽
3.1 (1.1– 8.3); P ⫽ 0.02]. The dose-response relationship between
lifetime gonadal exposure and bone sarcoma risk in males is
illustrated in Fig. 1, which shows the multivariate hazard function
curves for each of the gonadal exposure subgroups.
Body size was evaluated as a possible risk factor for bone
sarcoma in Rottweiler dogs. Adult height ranged from 58 to 76
cm (median ⫽ 66 cm) in 250 males and 48 to 79 cm (median ⫽
61 cm) in 329 females. Despite the wide variation in adult
height within the study population, this surrogate of skeletal
growth was not significantly associated with bone sarcoma in
males (P ⫽ 0.15) or females (P ⫽ 0.97). Adult body weight
ranged from 36 to 68 kg (median ⫽ 50 kg) in 293 males and 27
to 73 kg (median ⫽ 40 kg) in 384 females. Similar to adult
height, this measure of body size was not significantly associated with bone sarcoma in males (P ⫽ 0.15) or females (P ⫽
0.74). In addition, when dogs were stratified into four gonadal
exposure subgroups, adult height and body weight did not
significantly contribute to bone sarcoma risk in males or females (data not shown). In multivariate analysis, adult height
and body weight were not found to be significantly associated
with bone sarcoma development (Table 3).
Because duration of gonadal exposure significantly influenced risk of bone sarcoma, we investigated further the reproductive history of female dogs in this study. The reproductive
history of 275 female dogs that were sexually intact after 1 year
of age was obtained by telephone interview of owners (Table
5). Fifty percent of female dogs had at least one litter during
their lifetime and 50% were nulliparous. There was no signif-
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Table 2

Univariate analysis of risk factors of appendicular bone sarcoma in a cohort of 683 Rottweiler dogs

Risk Factor

Dogs with bone sarcoma

Dogs without bone sarcoma

Total no.
Gender
Male
Female
Neuter status
Intact male
Castrated male

86 dogs

597 dogs

35 dogs
51 dogs

Intact female
Spayed female
Lifetime gonadal exposure
Months intact (mean ⫾ SD)
Male
Female
Body size
Adult height (mean ⫾ SD)
Male
Female
Adult body weight (mean ⫾ SD)
Male
Female

Table 3

Hazard Ratio (95% CI)

P

259 dogs
338 dogs

1.00
1.01 (0.66–1.55)

0.97

10 dogs
25 dogs

120 dogs
139 dogs

1.00
1.86 (0.89–3.87)

0.10

5 dogs
46 dogs

64 dogs
274 dogs

1.00
0.95 (0.38–2.40)

0.91

53.1 ⫾ 44.3 mo
40.5 ⫾ 34.0 mo

71.1 ⫾ 42.7 mo
55.6 ⫾ 35.0 mo

0.98 (0.98–0.99)
0.98 (0.97–0.99)

⬍0.0001
⬍0.0001

61.0 ⫾ 2.8 cm
24.0 ⫾ 1.1 cm

65.8 ⫾ 2.8 cm
61.0 ⫾ 3.3 cm

1.10 (0.97–1.26)
1.00 (0.91–1.10)

0.15
0.97

50.5 ⫾ 7.6 kg
40.9 ⫾ 4.7 kg

49.7 ⫾ 5.7 kg
40.6 ⫾ 5.0 kg

1.04 (0.99–1.10)
1.01 (0.96–1.01)

0.15
0.74

Multivariate cox proportional hazard models of bone sarcoma in a
cohort of Rottweiler dogs

Model 1 (n ⫽ 578 dogs)
Gender
Months sexually intact
Adult height (cm)
Adult body weight (kg)
Model 2
Male (n ⫽ 202 dogs)
Months sexually intact
Adult height (cm)
Adult body weight (kg)
Female (n ⫽ 329 dogs)
Mo sexually intact
Adult height (cm)
Adult body weight (kg)

Hazard ratio (95% CI)

P

0.90 (0.48–1.69)
0.99 (0.98–0.99)
1.02 (0.93–1.10)
0.99 (0.94–1.05)

0.73
⬍0.0001
0.73
0.83

0.99 (0.98–1.00)
1.11 (0.95–1.29)
0.98 (0.90–1.07)

0.003
0.21
0.72

0.98 (0.98–0.99)
0.98 (0.89–1.08)
0.99 (0.93–1.06)

0.001
0.70
0.75

icant difference in bone sarcoma risk between females with
litters versus nulliparous females (P ⫽ 0.22). There were no
significant differences between dogs with bone sarcoma and
dogs without bone sarcoma with respect to number of years of
reproductive activity, number of litters, or number of puppies.
Age at first pregnancy was also similar between affected and
nonaffected dogs (P ⫽ 0.47). Supplementation of nine females
with exogenous hormones was not significantly associated with
risk of bone sarcoma (P ⫽ 0.56).
Discussion
Comparative oncologists seek to test important hypotheses by
studying the similarities and differences between the cancers that
affect humans and animals. We focused on the appendicular osteosarcomas that naturally occur in Rottweiler dogs because of the
striking biological similarities of this disease to its human counterpart. To our knowledge, this represents the first application of a
spontaneous model of bone sarcoma to investigate the role of
endogenous sex hormones in sarcomagenesis. In this study, we
found a strong inverse association between lifetime exposure to

gonadal hormones and risk of spontaneous bone sarcoma. Gonadal
hormone exposure was a significant risk factor of bone sarcoma
independent of adult body size, a previously recognized risk factor
for bone sarcoma. Importantly, this study identifies a high-risk
subpopulation of Rottweiler dogs that could be targeted to study
whether modifications in lifestyle or environmental factors reduce
the incidence of bone sarcoma.
Previous studies using dogs with spontaneous bone sarcoma have focused on the preclinical evaluation of novel therapeutics (19 –23). We have turned our attention to studying
possible host factors that contribute to the risk of bone sarcoma
development. Using a historical cohort study design, we evaluated bone sarcoma risk in ⬃700 Rottweiler dogs living in
North America. Rottweiler dogs were selected for this study
because (a) their risk of bone sarcoma is very high compared
with other breeds (17) and (b) ⬎85% of their appendicular bone
sarcomas are osteosarcoma.5 Our previous work has demonstrated the feasibility of using questionnaires to generate reliable data on exposures (e.g., diet, sex hormones, and environmental agents) and disease outcome in pet dogs (24 –26).
Similar to the situation in humans, relatively little is
known about factors that regulate bone sarcoma development in
pet dogs. Because many pet dogs undergo elective castration or
ovariohysterectomy as young animals, this population offers a
unique opportunity to compare individuals that differ dramatically with respect to lifetime testicular or ovarian hormone
exposure. Previous studies using pet dogs have clearly established a relationship between ovarian hormones and breast
cancer risk (27, 28). We conducted this study to critically
evaluate the dose-response relationship between gonadal hormone exposure and bone sarcoma risk because this could not be
studied within the human population at risk for osteosarcoma.
Our study, using a naturally occurring model of bone sarcoma,
shows that risk of bone sarcoma is significantly increased by
elective gonadectomy early in life. Exposure to endogenous sex
hormones appears to be protective, as suggested by the high
risk for bone sarcoma in male and female dogs that undergo

5

D. J. Waters, unpublished data.
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Table 4

a

Lifetime gonadal hormone exposure and bone sarcoma risk in a cohort of 683 Rottweiler dogs
Dogs with bone
sarcoma (no.)

Dogs without bone
sarcoma (no.)

Total
dog-months

Bone sarcoma incidence rate
(95% CI)a

86

597

71,004

12.1 (9.6–14.7)

RR (95% CI)

P

0.74

Total population
Gender
Male
Female
Male gonadal exposure subgroup
Castrated before 1 yr of age
Castrated 1–3.5 yr of age
Castrated after 3.5 yr of age
Sexually intact

35
51

259
338

30,228
40,776

11.6 (7.8–15.4)
12.5 (9.1–15.9)

1.0
1.1 (0.7–1.7)

9
8
8
10

25
57
57
120

3,168
6,228
7,632
13,212

28.4 (9.8–47.0)
12.8 (3.9–21.8)
10.5 (3.3–17.8)
7.6 (2.9–12.3)
P trend ⫽ 0.008

3.8 (1.5–9.2)
1.7 (0.7–4.3)
1.4 (0.6–3.5)
1.0

0.002
0.31
0.48

Female gonadal exposure subgroup
Spayed before 1 yr of age
Spayed 1–5 yr of age
Spayed after 5 yr of age
Sexually intact

18
14
14
5

57
108
108
64

7,176
12,612
14,856
6,144

25.1 (13.5–36.7)
11.1 (5.3–16.9)
9.4 (4.5–14.3)
8.1 (1.0–15.3)
P trend ⫽ 0.006

3.1 (1.1–8.3)
1.4 (0.5–3.8)
1.2 (0.4–3.2)
1.0

0.02
0.63
1.00

Incidence rate expressed as number of bone sarcomas per 10,000 dog-months.

Fig. 1. Multivariate hazard functions for bone sarcoma risk in male
Rottweiler dogs according to lifetime gonadal exposure.

gonadectomy within the first year of life. For each dog, we
could accurately obtain age at gonadectomy, which provided a
highly reliable measure of the duration of gonadal hormone
exposure. The possibility that dogs with the same number of
years of exposure to ovarian or testicular hormones had significant differences in circulating or target organ concentrations of
sex hormones cannot be excluded because serum and tissue
hormone concentrations were not measured.
There are very limited published data on Rottweiler dogs
with which to compare the population that we studied. One
study of dogs in Great Britain reported the median age at death
in 101 Rottweiler dogs was 9.8 years (compared with 9.5 years
in our study) and that Rottweilers had a ⬎2-fold increased risk
for cancer compared with other breeds (29). Our data were
collected from the owners and veterinarians of purebred Rottweiler dogs in North America. The high participation rate in
this study reflects the high degree of awareness and interest in
the bone cancer predisposition of this breed. The dogs in this
cohort underwent regular health examinations and received
high-quality medical care for health problems. Although this
study may overestimate the true incidence of bone sarcoma in

the overall Rottweiler population, it is not clear how the strong
inverse relationship that we found between gonadal exposure
and bone sarcoma risk reflects bias attributable to questionnaire
nonresponders. Pet owners who received questionnaires were
never informed of the hypothesis that sex hormones might
influence bone sarcoma risk. It is reasonable to conclude that
nonresponders had a minimal effect on the most important
implication of this work: the identification of a high risk target
population for bone sarcoma prevention. We believe that the
highly motivated pet owners who participated in this study were
likely to be quite representative of those who would enroll their
Rottweiler dogs in a bone sarcoma prevention trial.
Our finding that neutered Rottweiler dogs are at increased
risk for bone sarcoma is consistent with the findings of Ru et al.
(17). Using a computerized database from North American
Veterinary Teaching Hospitals from 1980 to 1994, a casecontrol study of 3062 osteosarcoma cases and 3959 control
dogs was conducted to evaluate risk factors of osteosarcoma in
purebred dogs of various breeds. Neutered dogs were at 2.2
times (95% CI ⫽ 2.0 –2.4) greater risk of osteosarcoma than
sexually intact dogs (17). Because the database used in that
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Table 5 Univariate analysis of reproductive risk factors of appendicular bone sarcoma in a cohort of 275 female Rottweiler dogs
Risk factor
Total no.
Pregnancy
Yes
No
Duration of reproductive activitya
No. of litters
No. of live births
Age at first pregnancy
a

Dogs with bone sarcoma

Dogs without bone sarcoma

28 dogs

247 dogs

11 dogs
17 dogs
2.6 ⫾ 1.5 yr
2.0 ⫾ 0.9 litters
10.2 ⫾ 6.5 puppies
3.4 ⫾ 1.2 yr

127 dogs
120 dogs
2.5 ⫾ 1.5 yr
2.1 ⫾ 1.1 litters
11.9 ⫾ 9.1 puppies
3.6 ⫾ 1.1 yr

P

0.22

0.97
0.79
0.54
0.47

Duration of reproductive activity ⫽ total number of years during which she was bred.

study provided no information on age at gonadectomy, the
study could not evaluate bone sarcoma risk in terms of duration
of gonadal hormone exposure. Our results indicate that dogs
undergoing early gonadectomy have the highest risk for bone
sarcoma development.
Little is known about how gonadal hormones or other host
factors regulate sarcomagenesis. To date, there is no definitive
evidence that a sequential multistep process, considered the hallmark of epithelial carcinogenesis (30), is operational in the transformation of mesenchymal cells. The possible mechanisms by
which gonadal hormone exposure might protect against the development of bone sarcoma in both males and females are not
immediately evident. Endogenous sex steroids such as estrogen
and testosterone may serve as prodifferentiation agents that inhibit
the malignant transformation of osteoblasts (31). Alternatively, the
inverse association may be attributable to indirect effects of sex
steroids on body conformation or physical activity. Although female dogs in the early gonadectomy subgroup reached the greatest
height as adults, neither adult height nor body weight were significant risk factors for bone sarcoma. Finally, yet to be identified
confounding factors unique to dogs that undergo elective gonadectomy before 1 year of age may account for this association.
Gonadectomized female and male dogs lived longer than sexually
intact dogs in this cohort (Table 1) and in a previous study (32),
which might be expected to contribute to a higher overall cancer
incidence associated with gonadectomy. However, in this cohort,
there was no statistically significant difference in the overall cancer incidence rate in male or female dogs that underwent early
gonadectomy before 1 year of age compared with sexually intact
dogs (data not shown). Among all cancer diagnoses, bone sarcoma
was overrepresented in the early gonadectomy subgroup, representing 27 of 45 (60%) cancer diagnoses compared with the
sexually intact group in which only 15 of 66 (23%) cancer diagnoses were bone sarcoma. We found no evidence indicating that
dogs in this cohort that underwent early gonadectomy received
increased medical surveillance that might translate into increased
likelihood of bone sarcoma diagnosis. In this population, there
were no apparent differences in the frequency or intensity of
veterinary services provided to dogs that underwent early gonadectomy and to those left sexually intact.
Several lines of evidence strengthen our confidence that
the inverse association between gonadal hormone exposure and
bone sarcoma risk may be causal. Because endogenous sex
steroids are essential for skeletal homeostasis (33–38), the
hypothesis that alterations in gonadal hormones might influence skeletal oncogenesis has biological plausibility. Secondly,
our data in both males and females indicate a consistent inverse
dose-response relationship between duration of gonadal exposure and incidence rate of bone sarcoma. Thirdly, there is
temporal compatibility between exposure and outcome. Dogs

that undergo gonadectomy within the first year of life have a
greater risk of bone sarcoma than dogs that undergo gonadectomy later in life. Most Rottweiler dogs are diagnosed with
bone sarcoma at age 8 –10 years, and no dogs in our study
developed bone sarcoma before the age of 1.3 years. Finally,
our finding of the possible protective effect of gonadal hormones on bone sarcoma in this study is supported by a previous
investigation using a different population of pet dogs (17).
Experimentally, exogenous sex hormones have been
shown to suppress (6, 39) or promote (40 – 43) bone sarcoma
development. The effect of exogenous estrogens on the development of radiation-induced bone sarcomas has been studied in
mice after i.p. 90Sr administration (43). Mice receiving s.c.
estrogens had significantly increased incidence of bone tumors.
In another study, mice fed estrogens (diethylstilbesterol and
estradiol) had an increased number of spontaneous bone sarcoma (6 tumors in 1242 mice) compared with mice fed control
diet (0 tumors in 356 mice; Ref. 40). No clear relationship
between bone sarcoma development and dose or duration of
dietary estradiol was found. The authors of that study acknowledged that the low incidence of spontaneous bone sarcoma
(0.48%) in estrogen-fed mice resulted in inadequate power to
reach statistical conclusions. Instead, we studied a population of
Rottweiler dogs with a high incidence (12.6%) of spontaneous
bone sarcoma. We focused on the role of endogenous sex
steroids, rather than exogenous hormones. In contrast to these
rodent studies, our results suggest that endogenous sex hormones have a protective effect on the spontaneous development
of bone sarcoma within a dog breed that is programmed for
high incidence of bone sarcoma. Although the gene-environment interactions that determine an individual’s risk to develop
bone cancer are poorly understood, our findings suggest that
gonadal hormones are part of the internal environment that may
significantly modify the risk for sarcomagenesis. For this reason, this work may have important implications for elucidating
the complex interactions between genetic and environmental
factors that regulate bone sarcomagenesis.
Thirty-five years ago, Tjalma (16) reported that the risk of
bone sarcoma in large and giant breed dogs exceeded that of small
breed dogs by as much as 185-fold. Although adult height and
body weight are strong predictors of bone sarcoma between different breeds of dogs, the association between skeletal growth or
body size and bone sarcoma risk had never been analyzed within
a breed. In this study, using univariate and multivariate analyses,
adult height and body weight were not significant risk factors of
bone sarcoma development. In fact, neither the tallest nor heaviest
adult Rottweiler dogs were at highest risk for bone sarcoma.
Because adult height and body weight were owner reported, interobserver variation may have obscured significant between
group differences in these parameters. Additional work is needed
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to determine whether quantitative measures of the rate or duration
of skeletal growth (e.g., length of the radius or other long bones;
age at physeal closure) are strongly associated with bone sarcoma
risk in Rottweiler dogs.
In summary, this study found that male and female Rottweilers with the shortest lifetime gonadal exposure had the
highest risk for bone sarcoma. Dogs that underwent early elective gonadectomy had a one in four lifetime risk of bone
sarcoma development compared with a significantly reduced
risk among dogs that were sexually intact throughout their
lifetime. Although it remains unclear how endogenous gonadal
hormones influence bone sarcoma development, our work provides the framework for selecting a target population for bone
sarcoma prevention studies. We have identified a subgroup of
Rottweiler dogs, recognizable as young adults, that are at high
risk to subsequently develop spontaneous bone sarcoma. With
the identification of this target population, practical clinical
trials using pet dogs can be designed to test whether chemoprevention strategies can significantly delay or prevent the
development of bone sarcoma. The conduct of such trials using
pet dogs will further validate the use of the comparative approach to develop and test novel strategies that will decrease
cancer-related mortality in humans.
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